View in EDS

Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023).

Saved in:
Bibliographic Details
Title: Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023).
Authors: Iannantuono, Giovanni Maria1 (AUTHOR), Floudas, Charalampos S.2 (AUTHOR), Filetti, Marco1 (AUTHOR), Giovagnoli, Tommaso1 (AUTHOR), Sganga, Stefano3,4 (AUTHOR), Vitale, Antonio3,4 (AUTHOR), Chandran, Elias5 (AUTHOR), Lombardi, Pasquale1,6 (AUTHOR), Rosenfeld, Roberto7 (AUTHOR), Giudice, Elena8 (AUTHOR), Xue, Elisabetta2 (AUTHOR), Rapisarda, Elvira9 (AUTHOR), Troisi, Paola3,4 (AUTHOR), Apolo, Andrea B.5 (AUTHOR), Karzai, Fatima5 (AUTHOR), Bria, Emilio3,10 (AUTHOR), Gulley, James L.2 (AUTHOR), Daniele, Gennaro1 (AUTHOR) gennaro.daniele@policlinicogemelli.it
Source: European Journal of Cancer. Jul2025, Vol. 225, pN.PAG-N.PAG. 1p.
Database: Academic Search Ultimate
Description
ISSN:09598049
DOI:10.1016/j.ejca.2025.115589